Cilastatin
- Generic Name
- Cilastatin
- Brand Names
- Primaxin, Recarbrio
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O5S
- CAS Number
- 82009-34-5
- Unique Ingredient Identifier
- 141A6AMN38
- Background
Cilastatin is an inhibitor of renal dehydropeptidase, an enzyme responsible for both the metabolism of thienamycin beta-lactam antibiotics as well as conversion of leukotriene D4 to leukotriene E4. Since the antibiotic, imipenem, is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its meta...
- Indication
Cilastatin is indicated, in combination with imipenem with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.
- Associated Conditions
- Bacterial Septicemia, Bone and Joint Infections, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Endocarditis caused by staphylococcus aureus, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Neutropenic Fever, Pyelonephritis, Skin and Subcutaneous Tissue Bacterial Infections, Surgical Site Infections, Uncomplicated Urinary Tract Infections, Hepatic abscess
- Associated Therapies
- -
Safety, Tolerability and Pharmacokinetic Profile of an Infusion of Cilastatin in Healthy Volunteers.
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Spherium Biomed
- Target Recruit Count
- 23
- Registration Number
- NCT03595189
- Locations
- 🇪🇸
Clinical Trials Unit, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
- Conditions
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2008-08-04
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 430
- Registration Number
- NCT00080496
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.